Medizinische Statistik Saarbrücken GbR
- Address
- lock Available on a paid plan
Medizinische Statistik Saarbrücken GbR
Medizinische Statistik Saarbrücken GbR is a specialized medical statistics research center dedicated to advancing clinical research through rigorous statistical methodology and data analysis. The center demonstrates particular expertise in oncology research, focusing on innovative approaches to cancer treatment optimization and patient stratification.
- Stage II colon and rectal cancer adjuvant therapy evaluation
- Circulating tumor DNA (ctDNA) biomarker research and clinical applications
- Disease-free survival analysis in oncology trials
The center's research portfolio includes the CIRCULATE study, which investigates the role of circulating tumor DNA positivity in guiding adjuvant therapy decisions for patients with UICC stage II colon cancer. This work exemplifies their commitment to precision medicine approaches, utilizing molecular biomarkers to optimize treatment strategies and improve outcomes for colorectal cancer patients following primary tumor resection.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medizinische Statistik Saarbrücken GbR
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Adjuvant Therapy with Capecitabine in Stage II Colon and Rectal Cancer Patients with ctDNA Positivity Post-Resection | Technische Universitat Dresden | Phase III | Not Recruiting | Dec 2019 | Jan 2026 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 1 | Unknown | 2019-12-04 | 2019-12-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.